FRANCISCO JOSE
HERMIDA PRADO
Investigador
GlaxoSmithKline (United Kingdom)
Londres, Reino UnidoGlaxoSmithKline (United Kingdom)-ko ikertzaileekin lankidetzan egindako argitalpenak (1)
2018
-
SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4
Nature Communications, Vol. 9, Núm. 1